Dr. Gurunadh Atmaram Vemulakonda, MD

Dr. Vemulakonda practices at Surgery Center Palo Alto in Palo Alto, California.

Dr. Vemulakonda's NPI, 1235157207, was assigned on July 18, 2006. Dr. Vemulakonda graduated from WashU Medicine in 2002. Dr. Vemulakonda holds California license A105147.

Dr. Vemulakonda's primary practice is Surgery Center Palo Alto, at 795 El Camino Real, Palo Alto, CA 94301. The practice phone is (650) 324-1832.

Dr. Vemulakonda's primary practice is Surgery Center Palo Alto in Palo Alto, California. Dr. Vemulakonda is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is Palo Alto Foundation Medical Group. Dmand AI also links Dr. Vemulakonda to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vemulakonda practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Vemulakonda's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Vemulakonda is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Vemulakonda's licenses on file in 3 states: California, Washington and Oregon.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Vemulakonda treats.

CMS data shows 18,017 Medicare services from Dr. Vemulakonda across 15 procedure codes in 2024, for 844 Medicare patients. Medicare paid $1,615,970 for them. Every service was in an office.

CMS counts 844 Medicare patients who saw Dr. Vemulakonda in 2024. The largest group is 75 to 84, with 328 patients. 71% of them have high cholesterol, and 66% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Vemulakonda's median patient age at 70, with 51% women.

In 2024, Dr. Vemulakonda wrote 371 Medicare Part D claims for 104 patients. 64% of them were for generic drugs. CMS names the drug for 306 of them, across 7 drugs with 11 or more claims each, at $15,677 in total drug cost. In 2023, CMS named 260 claims across 7 drugs.

Dr. Vemulakonda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Vemulakonda, published from 2013 to 2014. 2013 was the busiest year, with 2. The most frequent topics are Antifungal Agents, Cataract and Cataract Extraction. Dr. Vemulakonda's most frequent co-authors are Yevgeniy Vladimirovich Sychev, MD, Thomas A. Albini, MD and Ingrid Tina Chang, MD.

Dmand AI links Dr. Vemulakonda to 6 clinical trials, 6 of them phase 3 studies. Conditions studied include Diabetic Retinopathy and Diabetic Angiopathies. Jaeb Center for Health Research sponsors the most, 6.

CMS Open Payments shows 2 general payments to Dr. Vemulakonda from 2 drug and device companies from 2023 to 2025. Device or supply loans make up the largest share, 92% of the total. Carl Zeiss Meditec USA, Inc. paid the most, $294.

Dmand AI lists 1 award for Dr. Vemulakonda.

Dr. Vemulakonda graduated from WashU Medicine in 2002. Dr. Vemulakonda is a member of AAO and ASRS.

Dr. Vemulakonda is in network with 11 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.